Vertex Pops On ‘Remarkable’ Late-Stage Results – Investor’s Business Daily

Vertex stock popped early Tuesday on promising test results for a drug that could treat a chronic autoimmune disease that slowly destroys the kidneys. Over the course of 36 weeks, patients with IgA nephropathy who received under-the-skin shots of Vertex Pharmaceuticals’ (VRTX) povetacicept had a 52% reduction in proteinuria, or the amount of protein in their urine. High levels of…
